% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Krmer:903019,
      author       = {Krämer, Felicia and Gröner, Benedikt and Hoffmann, Chris
                      and Craig, Austin and Brugger, Melanie and Drzezga,
                      Alexander and Timmer, Marco and Neumaier, Felix and
                      Zlatopolskiy, Boris D. and Endepols, Heike and Neumaier,
                      Bernd},
      title        = {{E}valuation of 3-l- and 3-d-[18{F}]{F}luorophenylalanines
                      as {PET} {T}racers for {T}umor {I}maging},
      journal      = {Cancers},
      volume       = {13},
      number       = {23},
      issn         = {2072-6694},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {FZJ-2021-04748},
      pages        = {6030 -},
      year         = {2021},
      abstract     = {Purpose: The preclinical evaluation of 3-l- and
                      3-d-[18F]FPhe in comparison to [18F]FET, an established
                      tracer for tumor imaging. Methods: In vitro studies were
                      conducted with MCF-7, PC-3, and U87 MG human tumor cell
                      lines. In vivo µPET studies were conducted in healthy rats
                      with/without the inhibition of peripheral aromatic l-amino
                      acid decarboxylase by benserazide pretreatment (n = 3 each),
                      in mice bearing subcutaneous MCF-7 or PC-3 tumor xenografts
                      (n = 10), and in rats bearing orthotopic U87 MG tumor
                      xenografts (n = 14). Tracer accumulation was quantified by
                      SUVmax, SUVmean and tumor-to-brain ratios (TBrR). Results:
                      The uptake of 3-l-[18F]FPhe in MCF-7 and PC-3 cells was
                      significantly higher relative to [18F]FET. The uptake of all
                      three tracers was significantly reduced by the suppression
                      of amino acid transport systems L or ASC. 3-l-[18F]FPhe but
                      not 3-d-[18F]FPhe exhibited protein incorporation. In
                      benserazide-treated healthy rats, brain uptake after
                      42–120 min was significantly higher for 3-d-[18F]FPhe vs.
                      3-l-[18F]FPhe. [18F]FET showed significantly higher uptake
                      into subcutaneous MCF-7 tumors (52–60 min p.i.), while
                      early uptake into orthotopic U87 MG tumors was significantly
                      higher for 3-l-[18F]FPhe (SUVmax: 3-l-[18F]FPhe, 107.6 ±
                      11.3; 3-d-[18F]FPhe, 86.0 ± 4.3; [18F]FET, 90.2 ± 7.7).
                      Increased tumoral expression of LAT1 and ASCT2 was confirmed
                      immunohistologically. Conclusion: Both novel tracers enable
                      accurate tumor delineation with an imaging quality
                      comparable to [18F]FET.},
      cin          = {INM-5 / INM-2},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-5-20090406 / I:(DE-Juel1)INM-2-20090406},
      pnm          = {5253 - Neuroimaging (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5253},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {34885141},
      UT           = {WOS:000734552300001},
      doi          = {10.3390/cancers13236030},
      url          = {https://juser.fz-juelich.de/record/903019},
}